

APR 12 2002
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE
SAC-2

Atty Dkt. No. 037003/0276603

4/19/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson, et al.

Group Art Unit: 1644

Application No. 09/758,173

Filed: January 12, 2001

Title: HUMAN B7.1 SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS
EXPRESSING SAID ANTIBODIES

* * * * *

ELECTION REPLY AND AMENDMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action (Restriction) mailed on March 12, 2002, Applicants elect
without traverse species A, i.e., the administration of an anti-B7.1 antibody.

Also, Applicants introduce the following additional claims directed to the elected
invention.

SAC-2
--32. The method of claim 21 wherein the antibody is a primatized antibody having the
variable regions of the 16C10 antibody wherein said antibody has the variable sequences
contained in Figures 8a-8b, 9a-9b and 10a-10b.

B2
33. The method of claim 21 wherein the anti-B7 antibody is a monoclonal antibody
that specifically binds human B7.1, having a human gamma 4 constant domain.

34. The method of claim 33 wherein said constant domain contains a mutation in the
CH2 region that eliminates FcR binding and a mutation in the hinge region that enhances the
stability of the heavy chain disulfide bound interaction.

35. The method of claim 32 wherein said antibody is administered at a dosage ranging
from 0.05 to 100 mg/kg/day.

36. The method of claim 32 where said antibody is administered at a dosage ranging
from 0.5 to 100 mg/kg/day.--

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

Also, amend claim 30 as set forth below.

B1
30. (Amended) The method of claim 29 wherein parenterally includes intravenous, intraperitoneal, intramuscular, and subcutaneous administration.

It is believed that this is a complete response to the outstanding Restriction Requirement.

Respectfully submitted,
Pillsbury Winthrop LLP

Date: April 12, 2002

By: *R. L. T.*
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2200 Telephone
(703) 905-2500 Facsimile

APPENDIX

30. (Amended) The method of claim 29 wherein parenterally includes intravenous, intraperitoneal, intramuscular, and subcutaneous ~~and~~ rectal administration .